🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

A few days ago, we posted about some of the most common symptoms of lung cancer, but did you know there are also uncommon signs to watch out for? 🧐 While symptoms like persistent cough & shortness of breath are more widely known, some lesser-known symptoms might surprise you

Huge congratulations to our Division Chief, Dr. David Barbie, as well as Dr. Pasi Jänne, Dr. Aaron Hata, Dr. Eric Smith, Dr. Shunsuke Kitajima on this incredible grant award. Dana-Farber Dana-Farber News

Congratulations David Barbie and the Dana-Farber's Lowe Center for Thoracic Oncology team! They were awarded a $2.5 million, four-year research grant from the Lung Cancer Research Foundation and the IASLC. Read more here: bit.ly/48XoOAI

Congratulations to our very own @cslathan for earning the Fellows of ASCO distinction this quarter!

EGFR mutations are the most common actionable mutations in lung cancer, found in ~15% of cases. On average, people with EGFR lung cancer are: - Younger at diagnosis. - More likely to be women. - More likely to have Asian Ancestry. - Less likely to have a history of heavy

📰 ICYMI: A project led by David Barbie of Dana-Farber's Lowe Center for Thoracic Oncology, Dana-Farber is the first to receive the IASLC Lung Cancer Research Foundation Team Science Research Grant on the Next Step in the Cure of Oncogene-Driven Lung Cancers Award. ➡️ Learn more: buff.ly/3V69eNE #lcsm #LCAM #LungCancer

Very excited to announce the launch of the Center for RAS Therapeutics, led by Dr. Andy Aguirre and our own Dr. Alice Shaw, a thoracic oncologist in our group.

📰 ICYMI: A project led by David Barbie of Dana-Farber's Lowe Center for Thoracic Oncology, Dana-Farber is the first to receive the IASLC Lung Cancer Research Foundation Team Science Research Grant on the Next Step in the Cure of Oncogene-Driven Lung Cancers Award. ➡️ Learn more: buff.ly/3V69eNE #lcsm #LCAM #LungCancer

We’re thrilled to celebrate our own Narjust Florez, MD, FASCO for being recognized as a Rising Star Women Leader in Healthcare 2025 by Women We Admire! 🌟🏆 This honor highlights her passion, innovation, and dedication to mentoring the next generation of healthcare leaders.

Masterful presentation by Dr. Julia Rotow MD discussing the ever expanding #EGFR mt #NSCLC. How do we measure the cost of intensifying 1L treatment, and how will we navigate the numerous upcoming options in the 2L space? #lcam #lcsm #TTLC25 EGFR Resisters EGFR Resisters Research Summit EGFR Positive Lung Cancer UK IASLC

🚀 Experts vs AI: The ADC Challenge – Lung Cancer Edition 🧠🤖 ADCs are revolutionizing #lungcancer treatment—but can #AI keep up with expert oncologists? Find out in this interactive, CME-accredited satellite symposium! 📅 Today at #TTLC25 🔗 Register now:

DFCI Thoracic Oncology Team at #TTLC25! IASLC Julia Rotow MD Jacob sands Jia Luo, MD Narjust Florez, MD, FASCO David Barbie

We’re proud to be named on of Newsweek’s Greatest Workplaces for Women. This recognition reflects our commitment to fostering an inclusive and empowering workplace for all. bit.ly/4iLqEs9

🎉 Big news our #equalstudy is officially OPEN! 🧬 Hear from our ctDNA Program Manager, Courtney Mantz, as she introduces this groundbreaking study using a simple blood test to possibly detect EGFR+ lung cancer. 👥 Are you 40+ and identify as Hispanic/Latinx or East/Southeast

Congratulations to the AACR Scientific Achievement Awardees, including our own Dr. Alice Shaw.

In a new study published in Clinical Cancer Research, Dana-Farber researchers found the effects of immunotherapy can last after treatment stops in patients with advanced non-small cell lung cancer. Dana-Farber's Lowe Center for Thoracic Oncology Read more: bit.ly/3GhpAhM

At #AACR25, Jia Luo, MD, MD, Dana-Farber presents a late-breaking abstract on the clinical activity of daraxonrasib in KRAS mutant non-small cell lung cancer (#NSCLC), finding early clearance in circulating tumor DNA predicted partial response or stable disease.

⭐ Alice T. Shaw, MD, PhD, of Dana-Farber's Lowe Center for Thoracic Oncology, Dana-Farber, has received the AACR-Joseph H. Burchenal Award for Outstanding Achievement in Clinical Cancer Research at #AACR25! 👏 Congratulations, Dr. Shaw! ➡️ Learn more: lungcancerstoday.com/post/alice-t-s…

Join us tomorrow in the Hall C tomorrow ASCO ASCO TECAG Hem-Onc Fellows Network H.O.M.E Dana-Farber's Lowe Center for Thoracic Oncology #ASCO25

The Chen-Huang Center for EGFR-Mutant Lung Cancers’ webpage was created to offer resources specifically for patients diagnosed with an #EGFR mutation: dana-farber.org/cancer-care/tr… #LCSM #CancerResearch